tetrafluoroborate
Small moleculeexperimental
Tetrafluoroborate is the anion BF−4. This tetrahedral species is isoelectronic with tetrafluoroberyllate (BeF2−4), tetrafluoromethane (CF4), and tetrafluoroammonium (NF+4) and is valence isoelectronic with many stable and important species including the perchlorate anion, ClO−4, which is used in similar ways in the laboratory. It arises by the reaction of fluoride salts with the Lewis acid BF3, treatment of tetrafluoroboric acid with base, or by treatment of boric acid with hydrofluoric acid. — Wikipedia
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jun 16, 2017 (NCT03196518)
Timeline
2010s
- Jan 1, 2018
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Unspecified targetUnclear
Unclear
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaTetrafluoroborate ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03456908 | Phase 1/Phase 2 (Phase 2) | Mar 16, 2018 | Mayo Clinic |
| NCT03196518 | N/A | Jun 16, 2017 | Memorial Sloan-Kettering Cancer Center |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Mayo Clinic | Academic/Hospital | 1 | 1 | 1 | 2018 |
| Memorial Sloan-Kettering Cancer Center | Academic/Hospital | 1 | 1 | 1 | 2017 |
2 organizations
Page 1 / 1